FAQ - Carcinoma, Intraductal, Noninfiltrating
(Powered by Yahoo! Answers)

What are the treatment options for invasive Ductal Carcinoma In Situ?

I was diagnosed with invasive Ductal Carcinoma In Situ. It was 1.7 cm. in size. Had lumpectomy and lymph node biopsy. The pathology they did during surgery came back clean. I am very scared. Any information would be appreciated.
I thought the invasive diagnosis was unusual also, but I saw the breast biopsy report and that is what it said.

It is impossible to have “invasive Ductal Carcinoma In Situ” as in situ means non-invasive. Are you saying you have invasive ductal carcinoma AND DCIS? Treatment option should have been discussed with you before you had surgery as what kind of surgery you have is based on your decision. I think you need a other talk with your doctor.  (+ info)

Can I have a basal cell carcinoma on my foot?

Has this happened to anyone, what I thought was a wart is infact a basal cell carcinoma. How was it treated if this happened to you. Thanks.

Skin cancer is a major problem in the elderly. Squamous cell carcinoma (SCC), the second most common skin cancer, typically occurs in this age group. Despite a number of modalities readily available for treatment. Consequently, the search for novel treatments continues. To my knowledge, there are only 6 published reports of invasive SCC treated with 5-percent Imiquimod cream. (Imiquimod is a topically applied imidazoquiline immunomodulator that enhances both innate and cell-mediated immunity )
This is a clinical trial result that has details that may be of interest:- An 89-year-old woman presented with three lesions on her lower limbs. She had previous treatments for multiple basal cell carcinomas, actinic keratoses, Bowen disease, and invasive SCCs at various sites. The new lesions were on the left foot (one) and right lower leg (two) and all showed changes of poorly differentiated SCC histologically. She declined surgical excision; radiotherapy was felt to be a poor option. She was treated with 5-percent imiquimod cream, initially to just the lesion on the dorsum of the foot, for 8-12 hours at night for three nights each week (three times a week). Treatment was well tolerated by week 2, so the frequency was increased to five times a week, and all three lesions treated. Gradually, two lesions diminished in size. Treatment was continued until there was no clinical evidence of residual tumor at these sites (19 weeks) repeat biopsies showed only a focus of dysplastic cells with no invasion (dorsum, left foot), and epidermal hyperplasia with no significant cytological atypia (outer aspect, right lower leg) Neither now showed evidence of invasive SCC. After 16 months there was no recurrence of either lesion. The third lesion (right lower leg,) did not respond to topical imiquimod and was later surgically excised.
Hope this helps
Matador 89  (+ info)

Carcinoma of the sigmoid with invasion into adjacent tissue. What is the ICD 9 code for this?

Carcinoma of the sigmoid with invasion into adjacent tissue. What is the ICD 9 code for this?

You probably would need more specific information. There are many ICD-9 sites on the internet that would be of help to you. Would probably be close to 209.16 to 209.66, with more specifics.  (+ info)

What causes breast bloody discharge beside cancer or intraductal papilloma. Not sure if it was blood or a red?

spot cause no blood came off my fingers. What tests are used to diagnose this and I did go to a doctor- thanks The ultrasound showed nothing.

I found a very informative website that you should take a look at. Some of the information that I found is below.

Extremely watery or bloody breast discharge (or rust or amber colored breast discharge), and greenish -brown or black colored discharge may be indicative of abnormal breast tissue, inflammation of the breast tissue (mastitis), intraductal papilloma (a tiny, non-cancerous tumor in the milk duct), or breast cancer. Breast cancer is more common in women over 50 who are experiencing this type of discharge. Usually this condition only occurs in one breast at a time, and presents a higher risk of cancer or Paget's Disease if it is only coming from one duct in the nipple, and not all of them. However, it is important to bear in mind that a woman at any age can get Breast Cancer.

Hope this helps!  (+ info)

Has anyone had any experience in a cancer treatment called Torisel for Renal Cell Carcinoma?

My dad was diagnosed with Stage 4 Renal Cell Carcinoma. He started a treatment this week. The treatment is call Torisel. I wonder if anyone has any experience in this drug. If it worked for your loved one and if there was any side effects and how long did it take to have the side effects.

I believe this is one of the newer mTOR targeted therapy drugs. It is very new. You would probably get more response and better information by going to an online support group with other patients who are using this drug. Good luck.  (+ info)

Where in the body does neuroindocrin carcinoma originate?

My husband was diagnosed with this cancer. The tumor was in his neck in a lymph node. They removed it and biopsied it and thats when they said it's neuroindocrin carcinoma. They scheduled us for an appointment next week, but until then does anyone know anything about this cancer? Thank you much

check this out,you will get all the details.
http://en.wikipedia.org/wiki/Neuroendocrine_tumor#Classification_of_GEP-NETs_by_site_of_origin_and_by_symptom  (+ info)

What is the life expectancy for small cell carcinoma?

Hi. My mom was just diagnosed with small cell lung carcinoma (SCLC) and it is in the early stages THANKFULLY! however, i am only 17 and she is hesitant about giving me info and telling me what the future holds for our family, especially since she is a single parent. If you could please give me some info to help me better understand and how to help my mom beat this disease i would forever grateful!!! Life expectancy, treatment, and any encouragement techniques as she is very depressed. thank you all!!!!!!

Small cell grows quickly, much quicker than non small cell. but small cell responds better to chemo treatments. Your mom may be advised to also have WBR (whole brain radiation) as often lung cancer travels to the brain. Since caught very early, she has a good chance of ridding herself of cancer, but will have to have regular scans as recurrence is almost always. Attached is a yahoo lung cancer group, there you will find people that have beaten small cell and are still surviving and are N.E.D. (no evidence of disease) after a couple of years of treatment.  (+ info)

What is the treatment of choice for papillary carcinoma thyroid discovered in a hemi thyroidectomy specimen?

We operated on a patient whose FNAC was a colloid nodule.. She was a case of Solitary Thyroid nodule.. Hemithyroidectomy was the procedure done... The biopsy report came back as PAPILLARY CARCINOMA THYROID without extra thyroid spread.. What is the next step...To perform a completion Thyroidectomy or Radioablation?

Small thyroid carcinomas (< or = 1.5 cm), including microcarcinomas (< or = 1.0 cm) (n = 39), were found in 53 patients (41%) with a papillary (n = 130) and in 4 cases (4%) with a follicular (n = 110) carcinoma. The tumour was clinically manifested by palpability or by the presence of nodal metastases in 1/3 of patients. Concomitant diagnoses were colloid goitre (n = 24), cellular adenoma (n = 11), Graves' disease (n = 6), and Hashimoto's thyroiditis (n = 4). Nodal involvement, multifocal tumour, and extrathyroidal extent (pT4) were present in 9%, 19%, and 8% of cases respectively. Small follicular carcinomas were minimally invasive in all instances. According to the age-related prognostic TNM-classification, 52 patients (91%) were in the low risk category. 18% of the patients underwent uni- or bilateral partial lobectomy, 35% hemithyroidectomy, and 47% total thyroidectomy, according to the extent and nature of the concomitant benign disease, whereas hemi- or total thyroidectomy was performed in the patients with known cancer. Four of 5 patients with stage pT4 cancer and all patients with nodal involvement underwent total thyroidectomy with radioiodine (n = 8 [14%]). Postoperative morbidity was 0%. During the follow-up period of 1-17 (x = 5.5) years no tumour-related death and no serious recurrence was noted. One node recurrence was removed 1 year following treatment of a stage III pT1aN1b papillary carcinoma; the patient died 4 years later accidentally without residual disease. These results confirm that cases with a potentially favourable course can be defined and treated selectively by less radical measures. Small carcinomas (< or = 1.5 cm) belong to these favourable tumours with a cancer mortality rate of virtually 0%, and the aim of treatment is to prevent curable recurrences: node positivity is an important risk factor, and therefore radioiodine is reserved for carcinomas with nodal involvement and also for the occasional small pT4-tumour.
Materials and Methods :-
Thyroid tumor tissue was obtained at surgery from patients undergoing thyroidectomy (including hemi, subtotal, and total thyroidectomy). A pathologist dissected the tissue, and a small tumor tissue block from the dominant or suspicious nodule was snap-frozen in liquid nitrogen and stored at –80 C. The size and location of tumor samples were recorded in detail. All tumor samples were obtained with permission of and in accordance with the guidelines of our institutional review board, and informed consent was obtained from all patients. Histological classification was confirmed, the diagnosis was obtained from the final pathology report, and this diagnosis was reviewed and confirmed by an endocrine pathologist.

RNA extraction, purification, labeling, and hybridization

The methods described by Barden et al. (20) were employed for RNA extraction, purification, labeling, and hybridization. In brief, frozen tumor tissue was homogenized by sonication in TRIzol reagent (Invitrogen, Carlsbad, CA), and total RNA was prepared according to the manufacturer’s specifications. A total of 42 samples were analyzed by gene chip array (GeneChip Hu95 array, Affymetrix, Inc., Santa Clara, CA). The carcinoma samples included seven PTC and seven FVPTC. The benign samples consisted of 14 FA and seven hyperplastic nodules. An additional seven unknown samples were processed (blinded to preparer). All samples were processed in the same manner following the Affymetrix protocol. cDNA was synthesized from 8 µg sample RNA using T7 (dT)24 primer (GENSET Corp., La Jolla, CA). Second strand cDNA was then produced and purified. Biotin-labeled cRNA was made and used for hybridization to the Affymetrix oligonucleotide arrays. A sample aliquot was first hybridized to an Affymetrix test chip to confirm that the cRNA quality was adequate. All samples were of good quality. After staining with streptavidin-phycoerythrin, the chips were scanned in an HP ChipScanner (Affymetrix, Inc.) to detect hybridization signals.

Data analysis

The data were analyzed using MicroArray Suite version 5.0 (Affymetrix, Inc.). The intensity of each probe set of the array was captured, and the average intensity was calculated. Quantitative expression levels were calculated using intrachip-positive controls. Normalization of data was performed to account for variability in hybridization among duplicate probe sets and other hybridization artifacts. Transcripts were designated reliably detected (present) or not detected (absent) using the above analysis.

Data analysis was performed to identify genes that were differentially expressed between the papillary carcinoma (PTC and FVPTC) and benign groups (FA and hyperplasia). Data from the 21 benign tumors and 14 carcinomas that comprised the training set were used. First, the data were screened to identify signals counted as present by the Affymetrix software. These results were exported to GeneSpring (Silicon Genetics, Redwood City, CA), then analyzed with a parametric t test and multiple testing correction (Benjamini and Hochberg False Discovery Rate, with the P value set at <0.05), producing a gene list of 1149 genes differentially expressed. This list of 1149 differentially expressed genes was then used for unsupervised hierarchical clustering and statistical analysis. Cluster analysis was used to group the tumors based upon their similarities measured across the expression of 1149 genes.

To determine whether FVPTC could be differentiated from benign thyroid nodules, a second analysis, comparing only FVPTC tumors to benign thyroid nodules, was performed to identify genes differentially expressed between these groups. The data were exported to GeneSpring (Silicon Genetics) and using a nonparametric t test with a P value set at less than 0.01, the data were screened to produce a gene list of 843 differentially expressed genes between FVPTC and benign lesions. Finally, a similar analysis was performed to compare PTC to benign lesions. A total of 483 genes were differentially expressed between PTC and benign lesions. As described above, these gene lists were used for unsupervised hierarchical clustering and statistical analysis.

Evaluation of unknown samples

Once the hierarchical cluster analysis was established using gene expression profiles of differentially expressed genes in 35 tumors, the same analysis was performed on seven thyroid tumors (one PTC, four FVPTC, and two hyperplastic nodules) with investigators blinded to the final diagnosis. Gene profiles of the seven unknown tumors were produced using the 1149 differentially expressed genes for comparison. The unknown sample profiles were then added to the original 35 samples to create a combined group of 42 samples, which then underwent an unsupervised hierarchical clustering analysis.

To confirm the validity of the subset analysis of FVPTC vs. benign tumors, the unknown samples’ individual gene profiles were analyzed (excluding the one classical PTC), using the 843 differentially expressed genes produced by the analysis of FVPTC vs. benign tumors. The gene profiles of unknown samples combined with the test set (FVPTC vs. benign) samples underwent an unsupervised hierarchical cluster analysis, producing a dendrogram for the 34 samples. This same technique was repeated to analyze the PTC vs. benign tumor gene list. Unknown samples’ gene expression profiles were analyzed (excluding the four FVPTC) using the gene profile for 438 genes differentially expressed in the PTC vs. benign analysis. Once again the unknown samples were combined with the PTC vs. benign samples, and an unsupervised hierarchical clustering was performed. A dendrogram of the 31 samples (PTC vs. benign plus unknowns) was produced.

Semiquantitative RT-PCR

To verify the results of the Affymetrix gene chip array, a total of five genes were chosen that had expression levels with more than 2-fold difference, were implicated in the molecular pathogenesis of cancer, and had readily available primers or were made from the known mRNA sequences using Primer3 (21). One microgram of sample RNA was reverse transcribed with oligo(dT) primer in a total volume of 50 µl. A 1-µl aliquot of cDNA was used for PCR, and the product was electrophoresed in a 2.0% agarose gel and visualized with ethidium bromide and UV light. The band intensity for each sample was calculated using EagleSight software (version 3.2, Stratagene, La Jolla, CA), and a ratio of the intensity of the gene of interest to that of the housekeeping gene was calculated for each sample. These normalized intensity levels were then analyzed using a t test. The genes and primers are listed in Table 1.  (+ info)

Does anybody here know more about papillary carcinoma?

I had a thyroidectomy a couple of weeks ago & the biopsy showed that it'a a papillary carcinoma.I'm so paranoid.What should i do? Any information regarding this type of cancer will be very much appreciated.

Hi, I had that too! May '06 was my TT. I have two great sites for you....www.thyca.org is the national thyroid cancer site, and health.groups.yahoo.com/group/thyca is the "chat" room that I belong to where you can ask questions and get info and tons of support.
Always get copies of all your paperwork, including the surgeon's report. Get a good endocronologist. Your goal after RAI (radiation) will be to have a low TSH of .1 or lower...NOT "normal" (that is for people with thyroids, and many doctors do not know that) and if you are having RAI, you should go on the LID (low iodine diet) for two weeks before hand to help make your thyroid cancer cells hungry to eat up the radiation. Cancer is scary- and don't let you have anyone tell you "it's the good kind". it does have a very good long term prognosis....but you must be vigalant about it for the rest of you life. You will love these sites, and I look forward to seeing you in the thyca health group on line. good luck.  (+ info)

My family dr removed a mole and it was basel cell carcinoma. Could he have gotten all the cancer?

I am going to a dermatologist whom specializes in skin cancer, what is the chances i will have to have surgery?

There are many types of skin cancer. Some are very dangerous and some are not. My father has a cancerous mole removed and he was fine. Others are not so lucky. The problem with some skin cancers they go deep into the tissue and will require further treatments. Your dermatologist will explain what treatment plan if any he will advise for you. Tanning beds are very harmful stay away from them and also from the sun. Keep covered as much as possible.  (+ info)

1  2  3  4  5  

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.